Quickfire Q&A delivers in-person insights from congresses, bringing together expert perspectives on the studies and data shaping clinical practice.
In this episode, recorded at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, we speak to Sarah Premji, Assistant Director of Breast Cancer Research, Sarah Cannon Research Institute, Nashville, Tennessee, USA, about emerging breast cancer research and the wider trends shaping oncology care.
Key topics discussed include:
- PALMARES-2: Could continuing endocrine therapy and cyclin-dependent kinase 4/6 inhibition beyond progression extend outcomes in selected patients?
- Personalized oncology: How biomarkers, circulating tumor DNA, AI, and metabolic health could help tailor cancer care.
- OPTIMA: Could tumor biology improve chemotherapy selection in early-stage hormone receptor-positive breast cancer?
Read the latest issue of AMJ Oncology for more expert insights and highlights from ASCO 2026.
